Healthtech Solutions Inc. announces the incorporation of a new subsidiary called RevHeart Inc. The new subsidiary will conduct further research into finding a treatment for COVID-related heart muscle injury. RevHeart’s research team is developing the ability to identify and track myocardial deformities to enable implementation of a therapy to ameliorate and potentially repair myocardial damage, which directly supports the Company’s ongoing efforts to develop a treatment for COVID-related heart muscle injury. Based on positive results to date, RevHeart has filed a provisional patent application with the U.S. Patent and Trademark Office titled, 'System, Method and Apparatus for Stimulating Cardiac Muscle Injury Recovery.' RevHeart will carry on this research and development program with a goal of developing a combination therapy as a method of treatment for the detected myocardial injury. This includes a combination of stem cell therapy and electromagnetic field therapy, known as 'Entrainment.' Entrainment works by linking the patient’s abnormal heart rhythm together with a normal heart rhythm and gently encouraging the damaged heart rhythm to revert to a more normal rhythm.